Study Showing the Safety of Statin Drugs Is “Fundamentally Flawed”

statins-large_transek9vkm18v_rkiph9w2gmnpphkrvugymkltqq96r_vp8-1

A new article authored by Dr. Aseem Malhotra (among others) says that a Lancet study demonstrating the safety of statin drugs is very flawed.

Decades of misinformation on cholesterol and the gross exaggeration of statin benefits with downplaying of side effects has likely led to the overmedication of millions of people across the world.
– Dr. Aseem Malhotra

Earlier

Dr. Aseem Malhotra on BBC – We Should Eat a High-Fat Diet

Health Experts Demand That Doctors Start Learning About Nutrition

The Futility of Blood Sugar Lowering by Medications in T2D

“We Need a Healthy Dose of Lifestyle Medicine”

Videos with Dr. Malhotra

  • The Big Fat Fix
  • Killing for profit?
  • Should You Worry About High Cholesterol?

Videos about cholesterol

  • Statin Nation
  • Nutrition Nuggets to Combat Conventional Dietary Advice
  • Killing for profit?

2 comments

  1. Bob Niland
  2. Amanda
    I'm sorry, but did you read this article? It is extremely pro-statin and actually suggests that more studies should be done on populations as more and more people are being put on them. It is not a study at all. It is a journal review of the research that has been done and a push for more blind studies. Dr. Aseem Malhotra did was not a contributor to this paper. He is cited in the references twice: #10 and #22. Both references reflected negatively on Dr. Malhotra.
    "Not only have the limitations of observational studies4,6–9 often been underestimated when attributing adverse effects to treatment (such as misleading claims that statins cause side-effects in one-fifth of patients 10–12), but also the strengths of randomised trials with masked treatment allocation and systematic ascertainment of many different types of adverse event have been underestimated for the reliable assessment of the safety and efficacy of treatment.3,9,13–15" pp.2532-2533

    "It has been claimed that randomised trials yield underestimates of rates of side-effects because they exclude patients in whom the treatment being studied causes adverse effects (eg, patients with so-called “statin intolerance”).11,12,22–24,64,72–78 However, for treatments that are
    not yet on the market or that have not yet been widely adopted into routine practice (as was the case during the recruitment phase of many of the large clinical outcome trials of statins 65,79), few patients will have previously been exposed to the treatment and excluded because of having had problems with it." p.2537

Leave a reply

Reply to comment #0 by

Older posts